{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:25:09Z","timestamp":1793827509397,"version":"4.6.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Open Access funding enabled and organized by Projekt DEAL. This work was supported by the University of Witten-Herdecke Germany.","award":["Open Access funding enabled and organized by Projekt DEAL. This work was supported by the University of Witten-Herdecke Germany."],"award-info":[{"award-number":["Open Access funding enabled and organized by Projekt DEAL. This work was supported by the University of Witten-Herdecke Germany."]}]},{"name":"Private Universit\u00e4t Witten\/Herdecke gGmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Vinpocetine (VPN) is an ethyl apovincaminate that has anti-inflammatory and antioxidant effects by inhibiting the expression of nuclear factor kappa B (NF-\u03baB) and phosphodiesterase enzyme 1 (PDE-1). VPN is used in the management of stroke, dementia, and other neurodegenerative brain diseases. VPN may be effective in treating Parkinson\u2019s disease (PD). Therefore, this review aimed to clarify the mechanistic role of VPN in the management of PD. VPN has protective and restorative effects against neuronal injury by reducing neuroinflammation, and improvement of synaptic plasticity and cerebral blood flow. VPN protects dopaminergic neurons by reducing oxidative stress, lipid peroxidation, glutamate neurotoxicity, and regulation of Ca<jats:sup>+\u20092<\/jats:sup>overloads. VPN can alleviate PD neuropathology through its anti-inflammatory, antioxidant, antiapoptotic and neurogenic effects. VPN through inhibition of PDE1 improves cyclic adenosine monophosphate (cAMP)\/cyclic guanosine monophosphate (cGMP) signaling in the dopaminergic neurons of the substantia nigra (SN). VPN improves PD neuropathology through PDE1 inhibition with a subsequent increase of the cAMP\/cGMP signaling pathway. Therefore, increasing cAMP leads to antioxidant effects, while augmentation of cGMP by VPN leads to anti-inflammatory effects which reduced neurotoxicity and development of motor severity in PD. In conclusion, this review indicated that VPN could be effective in the management of PD.<\/jats:p>","DOI":"10.1007\/s11011-023-01254-y","type":"journal-article","created":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T06:02:01Z","timestamp":1687154521000},"page":"1831-1840","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["New insights on the potential effect of vinpocetine in Parkinson\u2019s disease: one of the neglected warden and baffling topics"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3097-2962","authenticated-orcid":false,"given":"Hayder M.","family":"Al-kuraishy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Alexiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9020-874X","authenticated-orcid":false,"given":"Marios","family":"Papadakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6351-594X","authenticated-orcid":false,"given":"Omnya","family":"Elhussieny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9555-7300","authenticated-orcid":false,"given":"Hebatallah M.","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7817-425X","authenticated-orcid":false,"given":"Gaber El-Saber","family":"Batiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,19]]},"reference":[{"key":"1254_CR1","doi-asserted-by":"publisher","first-page":"113330","DOI":"10.1016\/j.biopha.2022.113330","volume":"153","author":"K Abu-Elfotuh","year":"2022","unstructured":"Abu-Elfotuh K, Hamdan AME, Abbas AN, Alahmre ATS, Elewa MA, Masoud RAE, Ali AA, Othman M, Kamal MM, Hassan FAM (2022) Evaluating the neuroprotective activities of vinpocetine, punicalagin, niacin and vitamin E against behavioural and motor disabilities of manganese-induced Parkinson\u2019s disease in Sprague Dawley rats. Biomed Pharmacother 153:113330","journal-title":"Biomed Pharmacother"},{"key":"1254_CR2","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s00210-018-1552-y","volume":"391","author":"HI Ahmed","year":"2018","unstructured":"Ahmed HI, Abdel-Sattar SA, Zaky HS (2018) Vinpocetine halts ketamine-induced schizophrenia-like deficits in rats: impact on BDNF and GSK-3\u03b2\/\u03b2-catenin pathway. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 391:1327\u20131338","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"1254_CR3","unstructured":"Al-kuraishy HM, Al-Gareeb AI (2020) Vinpocetine and ischemic stroke. Ischemic stroke 27"},{"key":"1254_CR4","doi-asserted-by":"publisher","unstructured":"Al-Kuraishy HM, Al-Gareeb AI, Al-Nami MS (2019) Vinpocetine improves oxidative stress and pro-inflammatory mediators in acute kidney injury. Int J Prev Med 10:142. https:\/\/doi.org\/10.4103\/ijpvm.IJPVM_5_19","DOI":"10.4103\/ijpvm.IJPVM_5_19"},{"key":"1254_CR5","doi-asserted-by":"publisher","first-page":"e01063","DOI":"10.1002\/prp2.1063","volume":"11","author":"HM Al-kuraishy","year":"2023","unstructured":"Al-kuraishy HM, Al-Gareeb AI, Alexiou A, Papadakis M, Alsayegh AA, Almohmadi NH, Saad HM, Batiha GE-S (2023) Pros and cons for statins use and risk of Parkinson\u2019s disease: an updated perspective. Pharmacol Res Perspect 11:e01063","journal-title":"Pharmacol Res Perspect"},{"key":"1254_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/bc.bc_46_19","volume":"6","author":"HM Al-Kuraishy","year":"2020","unstructured":"Al-Kuraishy HM, Al-Gareeb AI, Naji MT, Al-Mamorry F (2020) Role of vinpocetine in ischemic stroke and poststroke outcomes: a critical review. Brain Circulation 6:1","journal-title":"Brain Circulation"},{"key":"1254_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2019.112571","volume":"208","author":"AA Ali","year":"2019","unstructured":"Ali AA, Ahmed HI, Khaleel SA, Abu-Elfotuh K (2019) Vinpocetine mitigates aluminum-induced cognitive impairment in socially isolated rats. Physiol Behav 208:112571","journal-title":"Physiol Behav"},{"key":"1254_CR8","doi-asserted-by":"publisher","unstructured":"Alrouji M, Al-Kuraishy HM, Al-Gareeb AI, Saad HM, Batiha GE-S (2023) A story of the potential effect of non-steroidal anti-inflammatory drugs (NSAIDs) in Parkinson\u2019s disease: beneficial or detrimental effects. Inflammopharmacology\u00a031: 673\u2013688. https:\/\/doi.org\/10.1007\/s10787-023-01192-2","DOI":"10.1007\/s10787-023-01192-2"},{"key":"1254_CR9","doi-asserted-by":"crossref","unstructured":"Batiha GE, Al-Gareeb AI, Rotimi D, Adeyemi OS, Al-Kuraishy HM (2022) Common NLRP3 inflammasome inhibitors and Covid-19: divide and conquer. Sci African 18:e01407","DOI":"10.1016\/j.sciaf.2022.e01407"},{"key":"1254_CR10","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s12010-022-04155-5","volume":"195","author":"S Biswas","year":"2023","unstructured":"Biswas S, Bagchi A (2023) Study of the effects of nicotine and caffeine for the treatment of Parkinson\u2019s disease. Appl Biochem Biotechnol 195:639\u2013654","journal-title":"Appl Biochem Biotechnol"},{"key":"1254_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fnana.2015.00091","volume":"9","author":"J Blesa","year":"2015","unstructured":"Blesa J, Trigo-Damas I, Quiroga-Varela A, Jackson-Lewis VR (2015) Oxidative stress and Parkinson\u2019s disease. Front Neuroanat 9:91","journal-title":"Front Neuroanat"},{"key":"1254_CR12","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1001\/jama.2021.10207","volume":"326","author":"B Bluett","year":"2021","unstructured":"Bluett B, Togasaki DM, Mihaila D, Evatt M, Rezak M, Jain S, Schwarzschild MA, Ascherio A, Casaceli C, Curhan GC (2021) Effect of urate-elevating inosine on early Parkinson disease progression: the SURE-PD3 randomized clinical trial. JAMA 326:926\u2013939","journal-title":"JAMA"},{"key":"1254_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0361-9230(00)00354-3","volume":"53","author":"P B\u00f6n\u00f6czk","year":"2000","unstructured":"B\u00f6n\u00f6czk P, Guly\u00e1s B, Adam-Vizi V, Nemes A, K\u00e1rp\u00e1ti E, Kiss B, Kap\u00e1s M, Sz\u00e1ntay C, Koncz I, Zelles T (2000) Role of sodium channel inhibition in neuroprotection: effect of vinpocetine. Brain Res Bull 53:245\u2013254","journal-title":"Brain Res Bull"},{"key":"1254_CR14","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.bbrc.2013.03.092","volume":"434","author":"Y Cai","year":"2013","unstructured":"Cai Y, Li J-D, Yan C (2013) Vinpocetine attenuates lipid accumulation and atherosclerosis formation. Biochem Biophys Res Commun 434:439\u2013443","journal-title":"Biochem Biophys Res Commun"},{"key":"1254_CR15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejphar.2009.08.027","volume":"620","author":"R Deshmukh","year":"2009","unstructured":"Deshmukh R, Sharma V, Mehan S, Sharma N, Bedi K (2009) Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine\u2014a PDE1 inhibitor. Eur J Pharmacol 620:49\u201356","journal-title":"Eur J Pharmacol"},{"key":"1254_CR16","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1093\/jpp\/rgab011","volume":"73","author":"SS El-Sayed","year":"2021","unstructured":"El-Sayed SS, El-Yamany MF, Salem HA, El-Sahar AE (2021) New insights into the effects of vinpocetine against neurobehavioral comorbidities in a rat model of temporal lobe epilepsy via the downregulation of the hippocampal PI3K\/mTOR signalling pathway. J Pharm Pharmacol 73:626\u2013640","journal-title":"J Pharm Pharmacol"},{"key":"1254_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-019-1670-6","volume":"17","author":"Z Fan","year":"2020","unstructured":"Fan Z, Pan Y-T, Zhang Z-Y, Yang H, Yu S-Y, Zheng Y, Ma J-H, Wang X-M (2020) Systemic activation of NLRP3 inflammasome and plasma \u03b1-synuclein levels are correlated with motor severity and progression in Parkinson\u2019s disease. J Neuroinflammation 17:1\u201310","journal-title":"J Neuroinflammation"},{"key":"1254_CR18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1046\/j.1468-1331.2001.00181.x","volume":"8","author":"V Feigin","year":"2001","unstructured":"Feigin V, Doronin B, Popova T, Gribatcheva E, Tchervov D (2001) Vinpocetine treatment in acute ischaemic stroke: a pilot single-blind randomized clinical trial. Eur J Neurol 8:81\u201385","journal-title":"Eur J Neurol"},{"key":"1254_CR19","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2174\/0929867321666131228221749","volume":"21","author":"A Garcia","year":"2014","unstructured":"Garcia A, Redondo M, Martinez A, Gil C (2014) Phosphodiesterase 10 inhibitors: new disease modifying drugs for Parkinson\u2019s disease? Curr Med Chem 21:1171\u20131187","journal-title":"Curr Med Chem"},{"key":"1254_CR20","first-page":"215","volume":"76","author":"S Garza-Morales","year":"2019","unstructured":"Garza-Morales S, Brice\u00f1o-Gonz\u00e1lez E, Ceja-Moreno H, Ruiz-Sandoval JL, G\u00f3ngora-Rivera F, Rodr\u00edguez-Leyva I, Alonso-Rivera CG (2019) Extended-release vinpocetine: a possible adjuvant treatment for focal onset epileptic seizures. Bol Med Hosp Infant Mex 76:215\u2013224","journal-title":"Bol Med Hosp Infant Mex"},{"key":"1254_CR21","first-page":"166","volume":"56","author":"D Hadjiev","year":"2003","unstructured":"Hadjiev D (2003) Asymptomatic ischemic cerebrovascular disorders and neuroprotection with vinpocetine. Ideggyogyaszati Sz 56:166\u2013172","journal-title":"Ideggyogyaszati Sz"},{"key":"1254_CR22","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/FJC.0000000000000945","volume":"77","author":"D Han","year":"2021","unstructured":"Han D, Wang J, Wen L, Sun M, Liu H, Gao Y (2021) Vinpocetine attenuates ischemic stroke through inhibiting NLRP3 inflammasome expression in mice. J Cardiovasc Pharmacol 77:208","journal-title":"J Cardiovasc Pharmacol"},{"key":"1254_CR23","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/ncpneuro0924","volume":"4","author":"C Henchcliffe","year":"2008","unstructured":"Henchcliffe C, Beal MF (2008) Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol 4:600\u2013609","journal-title":"Nat Clin Pract Neurol"},{"key":"1254_CR24","doi-asserted-by":"publisher","first-page":"S210","DOI":"10.1016\/S1353-8020(11)70065-7","volume":"18","author":"EC Hirsch","year":"2012","unstructured":"Hirsch EC, Vyas S, Hunot S (2012) Neuroinflammation in Parkinson\u2019s disease. Parkinsonism Relat Disord 18:S210\u2013S212","journal-title":"Parkinsonism Relat Disord"},{"key":"1254_CR25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S0002-9440(10)64553-1","volume":"157","author":"LJ Hsu","year":"2000","unstructured":"Hsu LJ, Sagara Y, Arroyo A, Rockenstein E, Sisk A, Mallory M, Wong J, Takenouchi T, Hashimoto M, Masliah E (2000) \u03b1-Synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 157:401\u2013410","journal-title":"Am J Pathol"},{"key":"1254_CR26","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s11011-018-0256-9","volume":"33","author":"IO Ishola","year":"2018","unstructured":"Ishola IO, Akinyede A, Adeluwa T, Micah C (2018) Novel action of vinpocetine in the prevention of paraquat-induced parkinsonism in mice: involvement of oxidative stress and neuroinflammation. Metab Brain Dis 33:1493\u20131500","journal-title":"Metab Brain Dis"},{"key":"1254_CR27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.neuro.2023.03.002","volume":"96","author":"I Ishola","year":"2023","unstructured":"Ishola I, Awogbindin I, Olubodun-Obadun T, Olajiga A, Adeyemi O (2023) Vinpocetine prevents rotenone-induced Parkinson disease motor and non-motor symptoms through attenuation of oxidative stress, neuroinflammation and \u03b1-synuclein expressions in rats. Neurotoxicology 96:37\u201352","journal-title":"Neurotoxicology"},{"key":"1254_CR28","doi-asserted-by":"publisher","first-page":"6796","DOI":"10.1016\/j.bmc.2009.08.041","volume":"17","author":"SS Laddha","year":"2009","unstructured":"Laddha SS, Bhatnagar SP (2009) A new therapeutic approach in Parkinson\u2019s disease: some novel quinazoline derivatives as dual selective phosphodiesterase 1 inhibitors and anti-inflammatory agents. Biorg Med Chem 17:6796\u20136802","journal-title":"Biorg Med Chem"},{"key":"1254_CR29","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.3892\/mmr.2014.2080","volume":"9","author":"DW Li","year":"2014","unstructured":"Li DW, Liu ZQ, Chen W, Yao M, Li GR (2014) Association of glycogen synthase kinase\u20133\u03b2 with Parkinson\u2019s disease. Mol Med Report 9:2043\u20132050","journal-title":"Mol Med Report"},{"key":"1254_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.exer.2014.07.003","volume":"127","author":"RT Liu","year":"2014","unstructured":"Liu RT, Wang A, To E, Gao J, Cao S, Cui JZ, Matsubara JA (2014) Vinpocetine inhibits amyloid-beta induced activation of NF-\u03baB, NLRP3 inflammasome and cytokine production in retinal pigment epithelial cells. Exp Eye Res 127:49\u201358","journal-title":"Exp Eye Res"},{"key":"1254_CR31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.55782\/ane-2022-004","volume":"82","author":"K Luhach","year":"2022","unstructured":"Luhach K, Kulkarni G, Singh V, Sharma B (2022) Vinpocetine ameliorates developmental hyperserotonemia induced behavioral and biochemical changes: role of neuronal function, inflammation, and oxidative stress. Acta Neurobiol Exp (Wars) 82:35\u201351","journal-title":"Acta Neurobiol Exp (Wars)"},{"key":"1254_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.107988","volume":"119","author":"KJ Meador","year":"2021","unstructured":"Meador KJ, Leeman-Markowski B, Medina AE, Illamola SM, Seliger J, Novak G, Lin C, Ivanisevic M, Razavi B, Marino S (2021) Vinpocetine, cognition, and epilepsy. Epilepsy Behav 119:107988","journal-title":"Epilepsy Behav"},{"key":"1254_CR33","doi-asserted-by":"publisher","first-page":"9921","DOI":"10.1073\/pnas.1005138107","volume":"107","author":"AE Medina","year":"2010","unstructured":"Medina AE (2010) Vinpocetine as a potent antiinflammatory agent. Proc Natl Acad Sci 107:9921\u20139922","journal-title":"Proc Natl Acad Sci"},{"key":"1254_CR34","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/s12035-019-01745-z","volume":"57","author":"JA Morales-Garcia","year":"2020","unstructured":"Morales-Garcia JA, Alonso-Gil S, Santos \u00c1, Perez-Castillo A (2020) Phosphodiesterase 7 regulation in cellular and rodent models of Parkinson\u2019s disease. Mol Neurobiol 57:806\u2013822","journal-title":"Mol Neurobiol"},{"key":"1254_CR35","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0301-0082(00)00014-9","volume":"63","author":"MG Murer","year":"2001","unstructured":"Murer MG, Yan Q, Raisman-Vozari R (2001) Brain-derived neurotrophic factor in the control human brain, and in Alzheimer\u2019s disease and Parkinson\u2019s disease. Prog Neurobiol 63:71\u2013124","journal-title":"Prog Neurobiol"},{"key":"1254_CR36","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1093\/brain\/awv219","volume":"138","author":"F Niccolini","year":"2015","unstructured":"Niccolini F, Foltynie T, Reis Marques T, Muhlert N, Tziortzi AC, Searle GE, Natesan S, Kapur S, Rabiner EA, Gunn RN (2015) Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson\u2019s disease. Brain 138:3003\u20133015","journal-title":"Brain"},{"key":"1254_CR37","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.autneu.2011.07.010","volume":"165","author":"F Niwa","year":"2011","unstructured":"Niwa F, Kuriyama N, Nakagawa M, Imanishi J (2011) Circadian rhythm of rest activity and autonomic nervous system activity at different stages in Parkinson\u2019s disease. Auton Neurosci 165:195\u2013200","journal-title":"Auton Neurosci"},{"key":"1254_CR38","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1007\/s12035-016-0355-8","volume":"55","author":"DN Nthenge-Ngumbau","year":"2018","unstructured":"Nthenge-Ngumbau DN, Mohanakumar KP (2018) Can cyclic nucleotide phosphodiesterase inhibitors be drugs for Parkinson\u2019s disease? Mol Neurobiol 55:822\u2013834","journal-title":"Mol Neurobiol"},{"key":"1254_CR39","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s12028-022-01499-y","volume":"37","author":"PK Panda","year":"2022","unstructured":"Panda PK, Ramachandran A, Panda P, Sharawat IK (2022) Safety and efficacy of vinpocetine as a neuroprotective agent in acute ischemic stroke: a systematic review and meta-analysis. Neurocrit Care 37:314\u2013325","journal-title":"Neurocrit Care"},{"key":"1254_CR40","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S1734-1140(11)70574-6","volume":"63","author":"S Patyar","year":"2011","unstructured":"Patyar S, Prakash A, Modi M, Medhi B (2011) Role of vinpocetine in cerebrovascular diseases. Pharmacol Rep 63:618\u2013628","journal-title":"Pharmacol Rep"},{"key":"1254_CR41","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10072-018-3592-y","volume":"40","author":"Z Ping","year":"2019","unstructured":"Ping Z, Xiaomu W, Xufang X, Liang S (2019) Vinpocetine regulates levels of circulating TLRs in Parkinson\u2019s disease patients. Neurol Sci 40:113\u2013120","journal-title":"Neurol Sci"},{"key":"1254_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag A-E, Lang AE (2017) Parkinson disease. Nat Rev Dis Primers 3:1\u201321","journal-title":"Nat Rev Dis Primers"},{"key":"1254_CR43","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.3233\/JPD-212594","volume":"11","author":"W Poewe","year":"2021","unstructured":"Poewe W, Volc D, Seppi K, Medori R, L\u00fchrs P, Kutzelnigg A, Djamshidian A, Thun-Hohenstein C, Meissner WG, Rascol O (2021) Safety and tolerability of active immunotherapy targeting \u03b1-synuclein with PD03A in patients with early Parkinson\u2019s disease: a randomized, placebo-controlled, phase 1 study. J Parkinsons Dis 11:1079\u20131089","journal-title":"J Parkinsons Dis"},{"key":"1254_CR44","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.brainres.2018.10.006","volume":"1704","author":"F Rahmani","year":"2019","unstructured":"Rahmani F, Saghazadeh A, Rahmani M, Teixeira AL, Rezaei N, Aghamollaii V, Ardebili HE (2019) Plasma levels of brain-derived neurotrophic factor in patients with Parkinson disease: a systematic review and meta-analysis. Brain Res 1704:127\u2013136","journal-title":"Brain Res"},{"key":"1254_CR45","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.cbi.2015.05.007","volume":"237","author":"KW Ruiz-Miyazawa","year":"2015","unstructured":"Ruiz-Miyazawa KW, Pinho-Ribeiro FA, Zarpelon AC, Staurengo-Ferrari L, Silva RL, Alves-Filho JC, Cunha TM, Cunha FQ, Casagrande R, Verri WA Jr (2015) Vinpocetine reduces lipopolysaccharide-induced inflammatory pain and neutrophil recruitment in mice by targeting oxidative stress, cytokines and NF-\u03baB. Chem Biol Interact 237:9\u201317","journal-title":"Chem Biol Interact"},{"key":"1254_CR46","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/10715760000300061","volume":"32","author":"MS Santos","year":"2000","unstructured":"Santos MS, Duarte AI, Moreira PI, Oliveira CR (2000) Synaptosomal response to oxidative stress: effect of vinpocetine. Free Radic Res 32:57\u201366","journal-title":"Free Radic Res"},{"key":"1254_CR47","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/mds.27414","volume":"33","author":"SP Sardi","year":"2018","unstructured":"Sardi SP, Cedarbaum JM, Brundin P (2018) Targeted therapies for Parkinson\u2019s disease: from genetics to the clinic. Mov Disord 33:684\u2013696","journal-title":"Mov Disord"},{"key":"1254_CR48","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41531-017-0032-2","volume":"3","author":"S Sarkar","year":"2017","unstructured":"Sarkar S, Malovic E, Harishchandra DS, Ghaisas S, Panicker N, Charli A, Palanisamy BN, Rokad D, Jin H, Anantharam V (2017) Mitochondrial impairment in microglia amplifies NLRP3 inflammasome proinflammatory signaling in cell culture and animal models of Parkinson\u2019s disease. npj Parkinson\u2019s Dis 3:30","journal-title":"npj Parkinson\u2019s Dis"},{"key":"1254_CR49","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1001\/jamaneurol.2016.0947","volume":"73","author":"R Savica","year":"2016","unstructured":"Savica R, Grossardt BR, Bower JH, Ahlskog JE, Rocca WA (2016) Time trends in the incidence of Parkinson disease. JAMA Neurol 73:981\u2013989","journal-title":"JAMA Neurol"},{"key":"1254_CR50","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1001\/archneurol.2010.135","volume":"67","author":"R Savica","year":"2010","unstructured":"Savica R, Rocca WA, Ahlskog JE (2010) When does Parkinson disease start? Arch Neurol 67:798\u2013801","journal-title":"Arch Neurol"},{"key":"1254_CR51","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1007\/s00415-009-5357-2","volume":"257","author":"P Scalzo","year":"2010","unstructured":"Scalzo P, K\u00fcmmer A, Bretas TL, Cardoso F, Teixeira AL (2010) Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson\u2019s disease. J Neurol 257:540\u2013545","journal-title":"J Neurol"},{"key":"1254_CR52","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/S1474-4422(21)00219-2","volume":"20","author":"Y Sharabi","year":"2021","unstructured":"Sharabi Y, Vatine GD, Ashkenazi A (2021) Parkinson\u2019s disease outside the brain: targeting the autonomic nervous system. Lancet Neurol 20:868\u2013876","journal-title":"Lancet Neurol"},{"key":"1254_CR53","doi-asserted-by":"publisher","first-page":"a009399","DOI":"10.1101\/cshperspect.a009399","volume":"2","author":"L Stefanis","year":"2012","unstructured":"Stefanis L (2012) \u03b1-Synuclein in Parkinson\u2019s disease. Cold Spring Harb Perspect Med 2:a009399","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1254_CR54","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/jnr.23894","volume":"95","author":"PC Swart","year":"2017","unstructured":"Swart PC, Currin CB, Russell VA, Dimatelis JJ (2017) Early ethanol exposure and vinpocetine treatment alter learning-and memory\u2010related proteins in the rat hippocampus and prefrontal cortex. J Neurosci Res 95:1204\u20131215","journal-title":"J Neurosci Res"},{"key":"1254_CR55","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jns.2004.11.053","volume":"229","author":"G Szil\u00e1gyi","year":"2005","unstructured":"Szil\u00e1gyi G, Nagy Z, Balkay L, Boros I, Emri M, Lehel S, M\u00e1ri\u00e1n T, Moln\u00e1r T, Szak\u00e1ll S, Tr\u00f3n L (2005) Effects of vinpocetine on the redistribution of cerebral blood flow and glucose metabolism in chronic ischemic stroke patients: a PET study. J Neurol Sci 229:275\u2013284","journal-title":"J Neurol Sci"},{"key":"1254_CR56","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.neuint.2008.08.003","volume":"53","author":"K T\u00e1rnok","year":"2008","unstructured":"T\u00e1rnok K, Kiss E, Luiten P, Nyakas C, Tihanyi K, Schlett K, Eisel U (2008) Effects of Vinpocetine on mitochondrial function and neuroprotection in primary cortical neurons. Neurochem Int 53:289\u2013295","journal-title":"Neurochem Int"},{"key":"1254_CR57","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jamaneurol.2013.6233","volume":"71","author":"MA Thenganatt","year":"2014","unstructured":"Thenganatt MA, Jankovic J (2014) Parkinson disease subtypes. JAMA Neurol 71:499\u2013504","journal-title":"JAMA Neurol"},{"key":"1254_CR58","doi-asserted-by":"crossref","unstructured":"Tiwari PC, Pal R (2022) The potential role of neuroinflammation and transcription factors in Parkinson disease. Dialogues Clin Neurosci 19:71\u201380","DOI":"10.31887\/DCNS.2017.19.1\/rpal"},{"key":"1254_CR59","first-page":"115","volume":"65","author":"A Valikovics","year":"2012","unstructured":"Valikovics A, Cs\u00e1nyi A, N\u00e9meth L (2012) Study of the effects of vinpocetin on cognitive functions. Ideggyogyaszati Sz 65:115\u2013120","journal-title":"Ideggyogyaszati Sz"},{"key":"1254_CR60","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/neup.12691","volume":"40","author":"K Wakabayashi","year":"2020","unstructured":"Wakabayashi K (2020) Where and how alpha-synuclein pathology spreads in Parkinson\u2019s disease. Neuropathology 40:415\u2013425","journal-title":"Neuropathology"},{"key":"1254_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40035-021-00265-y","volume":"10","author":"C Wang","year":"2021","unstructured":"Wang C, Yang T, Liang M, Xie J, Song N (2021) Astrocyte dysfunction in Parkinson\u2019s disease: from the perspectives of transmitted \u03b1-synuclein and genetic modulation. Transl Neurodegener 10:1\u201317","journal-title":"Transl Neurodegener"},{"key":"1254_CR62","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1016\/j.neuropharm.2007.03.017","volume":"52","author":"W Wang","year":"2007","unstructured":"Wang W, Yang Y, Ying C, Li W, Ruan H, Zhu X, You Y, Han Y, Chen R, Wang Y (2007) Inhibition of glycogen synthase kinase-3\u03b2 protects dopaminergic neurons from MPTP toxicity. Neuropharmacology 52:1678\u20131684","journal-title":"Neuropharmacology"},{"key":"1254_CR63","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.intimp.2018.12.019","volume":"67","author":"S Wang","year":"2019","unstructured":"Wang S, Yuan Y-H, Chen N-H, Wang H-B (2019) The mechanisms of NLRP3 inflammasome\/pyroptosis activation and their role in parkinson\u2019s disease. Int Immunopharmacol 67:458\u2013464","journal-title":"Int Immunopharmacol"},{"key":"1254_CR64","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.neulet.2014.02.045","volume":"566","author":"H Wang","year":"2014","unstructured":"Wang H, Zhang K, Zhao L, Tang J, Gao L, Wei Z (2014) Anti-inflammatory effects of vinpocetine on the functional expression of nuclear factor-kappa B and tumor necrosis factor-alpha in a rat model of cerebral ischemia\u2013reperfusion injury. Neurosci Lett 566:247\u2013251","journal-title":"Neurosci Lett"},{"key":"1254_CR65","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3389\/fnmol.2018.00236","volume":"11","author":"Z Wei","year":"2018","unstructured":"Wei Z, Li X, Li X, Liu Q, Cheng Y (2018) Oxidative stress in Parkinson\u2019s disease: a systematic review and meta-analysis. Front Mol Neurosci 11:236","journal-title":"Front Mol Neurosci"},{"key":"1254_CR66","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.parkreldis.2019.02.027","volume":"77","author":"H Wilson","year":"2020","unstructured":"Wilson H, Pagano G, Niccolini F, Muhlert N, Mehta MA, Searle G, Gunn RN, Rabiner EA, Foltynie T, Politis M (2020) The role of phosphodiesterase 4 in excessive daytime sleepiness in Parkinson\u2019s disease. Parkinsonism Relat Disord 77:163\u2013169","journal-title":"Parkinsonism Relat Disord"},{"key":"1254_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2019.152122","volume":"94","author":"Y Xu","year":"2019","unstructured":"Xu Y, Deng C, Zheng Y, Liu N, Fu B (2019) Applying vinpocetine to reverse synaptic ultrastructure by regulating BDNF-related PSD-95 in alleviating schizophrenia-like deficits in rat. Compr Psychiatry 94:152122","journal-title":"Compr Psychiatry"},{"key":"1254_CR68","first-page":"1","volume":"2021","author":"H Xu","year":"2021","unstructured":"Xu H, Wang E, Chen F, Xiao J, Wang M (2021) Neuroprotective phytochemicals in experimental ischemic stroke: mechanisms and potential clinical applications. Oxid Med Cell Longev 2021:1\u201345","journal-title":"Oxid Med Cell Longev"},{"key":"1254_CR69","doi-asserted-by":"publisher","first-page":"774","DOI":"10.4103\/0253-7613.103300","volume":"44","author":"SA Zaitone","year":"2012","unstructured":"Zaitone SA, Abo-Elmatty DM, Elshazly SM (2012) Piracetam and vinpocetine ameliorate rotenone-induced parkinsonism in rats. Indian J Pharmacol 44:774","journal-title":"Indian J Pharmacol"},{"key":"1254_CR70","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejphar.2017.11.041","volume":"819","author":"Y-s Zhang","year":"2018","unstructured":"Zhang Y-s, Li J-d, Yan C (2018) An update on vinpocetine: new discoveries and clinical implications. Eur J Pharmacol 819:30\u201334","journal-title":"Eur J Pharmacol"},{"key":"1254_CR71","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1017\/S1740925X12000129","volume":"7","author":"Y-Y Zhao","year":"2011","unstructured":"Zhao Y-Y, Yu J-Z, Li Q-Y, Ma C-G, Lu C-Z, Xiao B-G (2011) TSPO-specific ligand vinpocetine exerts a neuroprotective effect by suppressing microglial inflammation. Neuron Glia Biol 7:187\u2013197","journal-title":"Neuron Glia Biol"},{"key":"1254_CR72","doi-asserted-by":"crossref","unstructured":"Zhou Q, Guo D, Li X, Wang Y, Ye X, Xue S, Wang X (2020) Anti-inflammatory effects of vinpocetine in LPS-stimulated microglia via activation of AMPK. An Acad Bras Cienc 92(4)","DOI":"10.1590\/0001-3765202020200241"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-023-01254-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11011-023-01254-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-023-01254-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T14:42:57Z","timestamp":1729608177000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11011-023-01254-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,19]]},"references-count":72,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1254"],"URL":"https:\/\/doi.org\/10.1007\/s11011-023-01254-y","relation":{},"ISSN":["0885-7490","1573-7365"],"issn-type":[{"value":"0885-7490","type":"print"},{"value":"1573-7365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,19]]},"assertion":[{"value":"20 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}